In this study we show that high molecular weight kininogen (HK) inhibited a-thrombin-induced aggregation of human platelets in a dose-dependent manner with complete inhibition occurring at plasma concentration (0.67 p,mol/L) of HK. HK (0.67 kmol/L) also completely inhibited thrombin-induced cleavage of aggregin (M, = 100 Kd), a surface membrane protein that mediates adenosine diphosphate (ADP)-induced shape change, aggregation, and fibrinogen binding. The inhibition of HK was specific for a-and y-thrombin-induced platelet aggregation, because HK did not inhibit platelet aggregation induced by ADP, collagen, calcium ionophore (A23187). phorbol myristate acetate (PMA), PMA + A23187, or 9.1 1-methano derivative of prostaglandin H, (U46619). These effects were explained by the ability of HK, at physiologic concentration, t o completely inhibit binding of '=La-thrombin t o washed platelets. As a result of this action of HK, this plasma protein also completely inhibited thrombininduced secretion of adenosine triphosphate, blocked intracellular rise in Ca2+ in platelets exposed t o a-and y-thrombin, inhibited thrombin-induced platelet shape change, and blocked the ability of thrombin t o antagonize the increase in intracellular cyclic adenosine monophosphate (CAMP) levels induced by iloprost. Because elevation of CAMP is known t o N THE BASIS of the previous studies from our 0 laboratory and others, we have proposed that there are two pathways that can lead to exposure of the fibrinogen receptor and platelet aggregation.' The first is adenosine diphosphate (ADP)-dependent and is involved in aggregation by ADP: e~inephrine,~ ~ollagen,~ and thromboxane A,.5 Binding of ADP to a single surface membrane protein, aggregin (M, = 100 Kd), distinct from glycoprotein (GP) IIIa,6 causes a conformational change facilitating binding of fibrinogen to the platelet GP IIb/IIIa complex.2 This process is inhibited by 5'-p-fluorosulfonylbenzoyl adenosine (FSBA), an affinity analogue of ADP, which covalently modifies aggregir~.~ A second way of exposing inhibit binding of thrombin t o platelets, we established that HK did not increase the intracellular concentration of platelet CAMP. Finally, HK did not inhibit enzymatic activity of thrombin. To study the role of HK in the plasma environment, we used y-thrombin t o avoid fibrin formation by a-thrombin. Platelet aggregation induced by y-thrombin was also inhibited by HK in a dose-dependent manner. The EC, (concentration t o produce 50% of the maximum rate of aggregation) of y-thrombin for washed platelets was 7 nmol/L and increased t o 102 nmol/L when platelets were suspended in normal human plasma. The EC, for platelet aggregation induced by a-thrombin in plasma deficient in total kininogen was 40 nmol/L. When supplemented with HK at plasma concentration (0.67 pmol/L), the EC, increased to 90 nmol/L, a value similar to that for normal human plasma. These results indicate that (1) HK inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin t o platelets; (2) HK is a specific inhibitor of platelet aggregation induced by a-and y-thrombin; and (3) HK plays a role in modulating platelet aggregation stimulated by a-thrombin in plasma.
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fibrinogen receptors necessary for platelet aggregation is ADP-independent and involves proteolysis of aggregin. Direct proteolysis of aggregin by chymotrypsin' and calpain* leads to platelet aggregation when incubation mixtures containing platelets and these proteases are treated with fibrinogen. Thrombin ( 2 nmol/L) aggregates platelets in an ADP-independent manner by increasing intracellular CaZ', [Ca'+],, which activates calpah8 This process requires binding of thrombin to the high-affinity receptors.' The ensuing cleavage is indirect because it does not take place in isolated membranes and requires metabolic energy.' Moreover, aggregin is cleaved to peptides of molecular weight less than 1 Kd. This mode of cleavage of aggregin is atypical of the known limited proteolytic action of thrombin on other substrates, including GP V." We have recently provided evidence for the involvement of calpain in this digestion because thrombin induces calpain expression on the external face of the platelet membrane." Therefore, we examined whether high molecular weight kininogen (HK), a major plasma protease inhibitor of calpain(s)," which also binds reversibly to platelet^,'^ inhibited platelet aggregation and cleavage of aggregin induced by thrombin by inhibiting calpain expressed on platelet surface.
The study shows that HK inhibited platelet aggregation by thrombin and not by most other agonists. However, we found that HK inhibited the previously mentioned thrombininduced platelet responses by inhibiting binding of thrombin to intact washed platelets. Other thrombin-induced platelet responses, eg, secretion, shape change, and intracellular increase in calcium ions, were also inhibited by HK. Furthermore, the action of thrombin was also modulated in the plasma environment by HK. Platelet-rich plasma (PRP) was prepared by differential centrifugation (12% 30 minutes, 23°C) of fresh whole human blood drawn into acid/citrate/dextrose (citric acid 0.079 mol/L, sodium citrate 0.085 m o m , and dextrose 0.180 mol/L) in a ratio of 1 mL of anticoagulant solution per 9 mL of blood. Platelets used in aggregation studies were washed and their suspensions prepared by the modification of the method of Mustard et a1.16 Modification included incubation of PRP with prostaglandin E,, hirudine and apyrase, and two successive washes of platelets with Tyrode-albumin buffer containing hirudine and apyrase, and apyrase alone. Platelets used in thrombin-induced cleavage studies were prepared by a modification of the method of Mills et al." Modifications included washing of the platelets with Tyrode-albumin buffers devoid of BSA. Incubation time during washing steps was reduced to 15 minutes.
Chemical modification of platelets by FSBA or ['HIFSBA was performed as reported previously?
Platelet shape change and aggregation in the presence of agonists and/or inhibitors were performed at 37°C under constant stirring (1,100 rpm) conditions in a Chronolog (Lumi) aggrometer (Havertown, PA). The total volume of the incubation mixture in the sample cuvette was 500 pL and the platelet concentration was adjusted to 1 x 108/mL and 5 x 108/mL for the shape change and aggregation, respectively. Platelet shape change or aggregation was initiated by the addition of an agonoist to the sample cuvette. Shape change and aggregation data presented in this report represent the decrease or increase in the light transmission of platelet suspension with shape change and aggregation, respectively. Light transmission was calibrated in terms of millivolts of current signal set arbitrarily to a scale of 100.
Platelet isolation and washing.
Platelet labeling with FSBA.
Platelet shape change and platelet aggregation. ['HIFSBA-labeled intact platelets in the presence or absence of HK were incubated with an agonist at 37°C for 30 minutes. Following incubation, the cells were sedimented and suspended in a Tyrode-albumin buffer without Caz+ as reported previously? ['HIFSBA-labeled membranes were prepared, solubilized, and subjected to SDS-PAGE as reported previously.2
HKwas purified by the method of Kerbiriou and Griffin:' with the modification that 0.2 mol/L E-aminocaproic acid was included in all buffers and 2 mmol/L diisopropylflurophosphate was added to the pooled material before each step. HK on reduced SDS-PAGE was predominantly a single band with a molecular mass of 120 Kd with 2 98% purity, and with a specific activity of 12 to 20 coagulant U/mL.
Measurement of intracellular Ca2'. Concentrations of intracellular CaZ+ were measured spectrophotometrically using quin-2/AM (AM = acetoqmethyl ester) fluorophore as previously described? ATP release from the dense granules of platelets following exposure to agonists and/or inhibitors was measured by the commercial fireflyluciferase assay (Sigma). The assay was calibrated with a solution of ATP of known concentration by measuring percent light transmission in the absence of any agonisthhibitor.
Measurement of cyclic adenosine monophosphate (CAMP) in human platelets. PRP, apyrase, and hirudin8 were incubated with 1 mmol/L aspirin for 20 minutes at 23°C. Platelets were then isolated and washed as described by Puri et a1.' Washed platelets (1 x 10* platelets/lOO kL) were incubated in the presence or absence of HK (0.67 pmol/L) with each agonist (see Table 1 ). The reaction was terminated by the addition of an equalvolume of 10% trichloroacetic acid and the reaction mixture cooled in ice for 5 minutes. The 'Z51-a-thrombin binding to human platelets. 'ZSI-a-thrombin was prepared by the iodogen procedure described by Tandon et al? ' The efficiency of labeling of thrombin was determined by paper chromatography in 85% methanol. After chromatography the radioactivity in the regions corresponding to the solvent front and the point of sample application was determined. The efficiency of labeling was obtained by multiplying the fraction of radioactivity remaining at the point of application by 100. It was found to be 63.3%. '2SI-tbrombin retained fully its ability to clot fibrinogen and to hydrolyze the synthetic substrate, H-D-phenylalanine-pipecolyl-L-arginine-p-nitroanilide (S2238; Kabi). The radioiodinated thrombin showed essentially one band when subjected to SDS-PAGE. The specific radioactivity of the radioiodinated thrombin was 1.65
Purification of HK.
Measurement of adenosine triphosphate (ATP) release.
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RESULTS
Effect of HK on platelet aggregation and cleavage of aggregin induced by thrombin. The inhibition of a-thrombin-induced aggregation of washed unmodified platelets and FSBA-modified platelets and FSBA-modified platelets by HK was concentration-dependent (Fig 1) . HK, at normal plasma concentration (80 &mL or 0.67 p.mol/L,'* completely prevented platelet aggregation initiated by a-thrombin (Fig 1, inset) . We have previously shown that aggregin is completely cleaved after incubation with a-thrombin. ' We now find that HK (0.67 p.mol/L) completely inhibited cleavage of aggregin after exposure of [3H]FSBA-labeled platelets to thrombin (2 nmol/L) (Fig 2) . [ Effect of HK on binding of thrombin to platelets. To test the possibility that HK might prevent thrombin from interacting with its receptors, we investigated the binding of IzI-thrombin to washed intact platelets. The total binding was concentration-dependent with saturation observed at 1 nmol/L. Nonspecific binding at a 50-fold mol/L excess of unlabeled thrombin was 30% to 40% of total binding at concentrations higher than 0.5 nmolb. The binding observed with HK did not differ from the nonspecific binding. HK (350-fold mol/L excess) completely inhibited binding of lZI-thrombin to washed intact platelets (Fig 3) .
Increase in CAMP levels has been shown to inhibit binding of a-thrombin?' Therefore, we investigated whether the inhibitory effect of HK could be attributed to the effect of HK on intracellular platelet CAMP concentration. The cAMP in intact unstimulated platelets was not detectable (Table l) , in agreement with a previously reported value of only 1.6 pmol cAMP/109 platelets.u Iloprost, an analogue of prostaglandin I, and a known stimulator of adenylate cyclase, markedly increased the platelet CAMP levels in the presence of papaverine, a cAMP phosphodiesterase inhibitor.% We found that HK at plasma levels (0.67 p,mol/L) did not affect the ability of iloprost and papaverine to increase the platelet CAMP levels ( Table 1) . Thrombin (2 nmol/L) inhibited by 90% the intracellular rise in CAMP levels induced by iloprost (Table  1) . HK (0.67 pmol/L) blocked the ability of thrombin to antagonize the increase in intracellular CAMP levels induced by iloprost.
Effect of HK on thrombin-induced secretion of ATP.
Thrombin (2 nmol/L) alone caused secretion of 5.2 pmol/L ATP (Table 2 ) from washed intact platelets. Thrombininduced ATP secretion was inhibited by HK (0.067 to 0.67 pmol/L) in a concentration-dependent manner and was complete at physiologic concentration (0.67 pmol/L) (Table 2). Effect of HK on the thrombin-induced increase in intracellular levels of Cat+. When platelets were incubated with a-thrombin, an elevation of intracellular calcium ([Ca'+],) corresponding to almost 1 pmol/L was observed (Table 3) . Preincubation of platelets with HK (0.67 pmol/L) for 1 minute completely blocked the thrombin-induced increase in [Ca"],. Addition of HK to the incubation mixture containing thrombin and platelets after 10, 20, and 30 seconds led to an increase in [Ca'+], by 23%, 39%, and 68%, respectively (experiments 3, 4, and 5, Table 3 ). These results suggest that once a certain number of receptors on the platelet surface are occupied by thrombin, and with the increase in [Ca'+], being so rapid, HK was unable to reverse this effect. HK (0.67 pmol/L) also completely inhibited the increase in [Ca'+], induced by y-thrombin (data not shown).
Effect of HK on thrombin-induced platelet shape change.
A very small increase in [Ca'+], is associated with platelet shape change." We found that thrombin, at a concentration as low as 0.031 nmol/L, induced platelet shape change (Table 4) Inhibition of thrombin-induced platelet aggregation by HK in plasma. To define the role of HK in the plasma environment, we made use of plasma with a varying amount of HK. Because fibrinogen is present in the various plasmas used, we used y-thrombin, an autolytic derivative of a-thrombin, because the former has little or no clotting activity.% HK inhibited y-thrombin-induced platelet aggregation in a dose-dependent manner (Fig 4) , with complete inhibition at 70 pg/mL (0.59 p.mol/L). The IC,, (0.24 kmol/L) of HK for platelet aggregation stimulated by y-thrombin was only slightly lower than the IC,, for a-thrombin (0.32 nmol/L) (Fig 1) . HK had no effect on the amidolytic activity of y-thrombin.
The effect of y-thrombin on thrombin-induced platelet 4).
lets versus concentration of thrombin.
aggregation in various plasmas is shown in Fig 5. The EC,, of y-thrombin (concentration to produce 50% of maximum rate of aggregation) was 7 nmoVL in washed platelets (curve 1, Fig 5) and 102 nmol/L, a 14.5-fold increase, when the same platelets were suspended in pooled normal plasma (curve 6, Fig 5) . When washed platelets were suspended in total kininogen-deficient plasma, the EC,, of y-thrombin to induce platelet aggregation was 40 nmol/L (curve 2, Fig 5) and was comparable with the EC,, value of 50 nmol/L for the plasma deficient only in HK (curve 3, Fig  5) . When plasma deficient in both kininogens was supplemented with HK (0.67 kmol/L) at the plasma concentration, the EC,, of y-thrombin increased to 90 nmol/L (curve 4 , Fig 5) , a value closer to that for normal human plasma. These results show that HK plays a significant role in modulating thrombin activity in plasma. Intracellular cAMP in intact washed platelets in the absence (experiment 10) and presence of HK (experiment 3) was measured as described in Materials and Methods. Platelets were then treated with iloprost and papaverine in the absence (experiment 1) and presence of HK (experiment 4) before determination of CAMP. Platelets were then treated with thrombin alone (experiment 5). and thrombin and iloprost plus papaverine (experiment 6). and cAMP levels were determined. Finally, platelets were preincubated with HK and then treated with thrombin followed by iloprost plus papaverine, and cAMP levels were determined. The results are expressed as mean 5 SE. Experiments were performed in triplicate.
For Platelets (2 x 108/500 JLL) were treated with buffer + thrombin (2 nmol/L), and ATP release measured by the firefly-luciferase procedure as described in Materialsand Methods (experiment 1). Platelets (2 x lo8/ 500 pL) were then preincubated with increasing concentrations of HK (experiments 2 through 6) at 37°C for 1 minute followed by a fixed concentration of thrombin (2 nmol/L), and ATP release was determined.
DISCUSSION
We recently showed that cleavage of aggregin in [3H]FSBA-labeled platelets as well as unmodified platelets during platelet aggregation induced by thrombin is indirectly mediated by the intracellularly activated calciumdependent cysteine protease, calpain.8 Platelet aggregation and cleavage of aggregin by a-thrombin are also mediated by the high-affinity thrombin receptors on the platelet s~r f a c e .~ Because HK was previously shown to be the most potent plasma inhibitor of platelet calpain,I2 we postulated that HK, at plasma concentration (0.67 kmol/L), might inhibit thrombin-induced platelet aggregation and cleavage of aggregin. In fact, HK inhibited thrombin-induced platelet aggregation of both unmodified and FSBA-modified platelets in a dose-dependent manner, with complete inhibition occurring at a plasma concentration of 0.67 KmoVL. HK, at normal plasma concentration (0.67 pmol/L), also completely inhibited thrombin-induced cleavage of aggregin in [3H]FSBA-modified platelets. HK did not inhibit amidolytic activity of a-and y-thrombin.
We then found that HK inhibited binding of lUIthrombin to washed intact platelets (Fig 3) . This is consistent with our previous findings that cleavage of aggregin requires occupancy of high-affinity receptors by thrombin.' Therefore, we examined whether or not HK inhibited other thrombin-induced platelet responses. We found that HK neither increased platelet CAMP levels nor did it affect the ability of iloprost to increase platelet CAMP levels. HK also blocked the ability of thrombin to antagonize adenylate cyclase receptor linked to that enzyme. Thrombin-induced 
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Platelets (2 x 108/mL) were treated with different concentrations of thrombin (experiments 1 through 7) to determine the optimum concentration of the protease necessary to give maximum shape change. HK itself did not cause platelet shape change (experiment 8). Shape change was then determined in platelets preincubated with HK (670-fold mol/L excess) followed by treatment with thrombin (experiment 9). The small degree of shape change observed in this case may be because of residual thrombin that have escaped neutralization by HK during the time period of incubation (30 seconds).
ATP secretion by the platelet dense granules was inhibited by HK in a concentration-dependent manner as well as by a thrombin-induced increase in [Ca2+Ii and shape change.
HK did not inhibit platelet aggregation induced by the agonists that function by ADP-dependent mechanisms, eg, ADP,' collagen: and U46619: or by the ones that function by mechanisms involving activation of protein kinase C and/or modulation of protein kinase C activity, eg PMA,"
and PMA + A23187,28 respectively.
The calcium ionophore A23187 is known to affect platelet shape change, aggregation, and secretion (reference 29, and other references cited therein). However, HK did not inhibit platelet aggregation induced by A23187 in the absence of added calcium. On the other hand, in the presence of external Ca2+ (5 mmol/L), A23187 has been shown previously to activate platelet calpain and cleave membrane and surface GPs." Consistent with these findings are our results that show that HK partially inhibited platelet aggregation and cleavage of aggregin induced by A23187 + Ca". Therefore, HK has the potential of inhibiting platelet aggregation induced by agonist(s) that increase intracellular Ca2+ high enough to activate platelet Platelets (2 x 108/mL) were treated with thrombin (experiment 1) and increase in [Ca'+], determined by the quin-S/AM procedure described in Materials and Methods. Platelets were preincubated with a plasma concentration of HK at 37°C for 1 minute followed by thrombin (experiment 2) and the increase in [Ca2+], was determined. In the next three experiments (3 through 5). platelets were treated with the same concentration of thrombin, but HK was added at different intervals after the addition of protease. Data are presented as the mean of duplicate measurements. calpain and translocate it onto the outer side of the membrane. Although thrombin-induced platelet aggregation proceeds by this mechanism8a9 and HK inhibits it, it does so by inhibiting binding of thrombin to platelets, an event that precedes and prevents the activation of calpain. Finally, we evaluated the significance of HK as a modulator of the effects of thrombin on platelets in plasma. To study HK in plasma, we used y-thrombin, which can stimulate platelets but does not convert fibrinogen into fibrinsz6 Crouch and Lapetina3' showed that y-thrombin is nearly as potent as a-thrombin in eliciting platelet activation. The EC,, of y-thrombin to stimulate platelet aggregation in pooled normal plasma (102 nmol/L) is almost 15 times that for washed platelets (7 nmol/L) (Fig 5) . The finding that EC,, of y-thrombin for HK-low molecular weight kininogen (LK)-deficient plasma (40 nmol/L) is close to that for plasma deficient only in HK (50 nmoVL), and that the EC,, of y-thrombin for HK-LK-deficient plasma reconstituted with 0.67 pmol/L HK (90 nmol/L) is close to that of the normal pooled plasma (102 nmol/L) (Fig  5) , suggests that HK is a modulator of thrombin-induced platelet aggregation in plasma. The difference between the potency of y-thrombin for total kininogen-deficient plasma and plasma deficient only in HK (Fig 5) is consistent with preliminary findings of other investigators3' that LK may also contribute, though less significantly, to the inhibition of thrombin-induced platelet aggregation in plasma. It is likely that LK, which has the identical heavy chain to that of HK, also inhibits binding of thrombin to platelets. The possibility that antithrombin I11 (in the absence of heparin) modulates thrombin-induced platelet aggregation in normal human plasma is less likely because antithrombin I11 has been previously shown to inhibit thrombin activity by less than 15% in 5 while the rate of thrombininduced platelet aggregation reaches a maximum value in less than 1 minute. The concentration of antithrombin I11 in various plasmas may be different, but the reconstitution data presented in Fig 5 show that HK alone can shift the dose-response curve for platelet aggregation by y-thrombin without altering the concentration of antithrombin 111.
In summary, we conclude that (1) HK is a specific inhibitor of thrombin-induced platelet aggregation; ( 2 ) HK inhibits thrombin-induced platelet aggregation by inhibiting binding of thrombin to platelets; and (3) HK plays an important role in modulating thrombin-induced platelet activation in human plasma.
